We aimed to determine risk factors for thrombotic events in early/prefibrotic myelofibrosis diagnosed according to the World Health Organization criteria. Multivariate Cox regression analysis was calculated on a total number of 264 patients derived from an international database. After a median follow-up of 6.28 years, 42 (15.9%) patients experienced arterial (n = 31) or venous thrombosis (n = 11). A higher leukocyte count correlated with an increased risk for total thrombosis and in particular, with an increased risk for arterial thrombosis (P = 0.005, HR 1.15 and P = 0.047, HR 1.12, respectively). A platelet count above 870 7 10(9) /L was associated with a lower risk for total thrombosis and also for venous thrombosis (P = 0.022, HR 0.44...
The clinical course of myelofibrosis (MF) may be complicated by both arterial and venous (sometimes ...
An underlying myeloproliferative disorder (MPD), especially polycythemia vera (PV) or essential thro...
Background Essential thrombocythemia is a chronic myeloproliferative disorder; patients with this d...
We aimed to determine risk factors for thrombotic events in early/prefibrotic myelofibrosis diagnose...
BACKGROUND: Vascular events represent the most frequent complications of thrombocytemias. We aim...
In an international study of 1104 patients with essential thrombocythemia (ET), a histological revie...
Background Vascular complications are a recognized cause of morbidity and mortality in Myelofibrosi...
There is evidence that leukocytosis is associated with an increased risk of first thrombosis in pati...
There is evidence that leukocytosis is associated with an increased risk of first thrombosis in pati...
This study investigates disease characteristics and clinical outcome in young patients (<40 years) w...
The recently revised World Health Organization (WHO) classification of myeloid neoplasms recognizes ...
The clinical course of myelofibrosis (MF) may be complicated by both arterial and venous (sometimes ...
An underlying myeloproliferative disorder (MPD), especially polycythemia vera (PV) or essential thro...
Background Essential thrombocythemia is a chronic myeloproliferative disorder; patients with this d...
We aimed to determine risk factors for thrombotic events in early/prefibrotic myelofibrosis diagnose...
BACKGROUND: Vascular events represent the most frequent complications of thrombocytemias. We aim...
In an international study of 1104 patients with essential thrombocythemia (ET), a histological revie...
Background Vascular complications are a recognized cause of morbidity and mortality in Myelofibrosi...
There is evidence that leukocytosis is associated with an increased risk of first thrombosis in pati...
There is evidence that leukocytosis is associated with an increased risk of first thrombosis in pati...
This study investigates disease characteristics and clinical outcome in young patients (<40 years) w...
The recently revised World Health Organization (WHO) classification of myeloid neoplasms recognizes ...
The clinical course of myelofibrosis (MF) may be complicated by both arterial and venous (sometimes ...
An underlying myeloproliferative disorder (MPD), especially polycythemia vera (PV) or essential thro...
Background Essential thrombocythemia is a chronic myeloproliferative disorder; patients with this d...